

Ilumya Order Form (tildrakizumab-asmn)

FAX TO: 972.499.9210

illusion (* * * * * * * * * * * * * * * * * * *				
PATIENT INFORMATION				
Patient Name:	DOB:	Phone:	Sex: M F Ht:	Wt: lbs kg
Primary Language:	Allergies:			
Patient Preferred Location:				
<icd 10="" code="" required=""></icd>	DIAGNOSIS & CI	LINICAL INFORM	ATION	
ICD 10 Code L40.0 Psoriasis Vulgaris L40.1 Generalized Pustular Psoriasis L40.2 Acrodermatitis Continua L40.3 Pustulosis Palmaris et Plantaris L40.4 Guttate Psoriasis L40.8 Flexural Psoriasis L40.9 Psoriasis, Unspecified Other:			e TB, annually will draw required maintena ed by Referring Provider	ance labs unless
<u>REQUIRED</u> : Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. <u>LAB RESULTS:</u> Include Negative TB within 12 months.				
PRESCRIPTION				
ILUMYA (tildrakizumab-asmn)				
Loading Dose SubQ: Inject 100 mg at weeks 0 and 4				
Maintenance Dose SubQ: Inject 100 mg every 12 weeks for one year				
Post Treatment Observations: The patient is observed for 30 minutes following the first administration.				
Adverse Events: In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.				
Comments:				
PRESCRIBER INFORMATION				
Prescriber Name: Signature:				
Date:NPI #:				
Supervising Physician:				
Address:				, , , ,
Contact Name:	•			·